Immunological markers of cancer vaccine efficacy and their clinical relevance

Biomarkers in Medicine

Volumn 3, Issue 3, 2009, Pages 253-264

  Cipriani, Barbara ^a  

^a IRBM   (Italy)

Author keywords

Complete response; Dendritic cells; Immune response; Intracellular; Myeloid derived suppressor cells; Progressive disease; Sentinel immunized lymph nodes; Stable disease; Staining; Tumor associated antigen; Tumor infiltrating lymphocytes

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DENDRITIC CELL VACCINE; DNA VACCINE; GEMCITABINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA A3 ANTIGEN; IDM 2101; IPILUMIMAB; MELAN A; PEPTIDE VACCINE; PROTEIN HUMAN TERT1540; PROTEIN TERT572; PROTEIN TERT572Y; SURVIVIN; SURVIVIN 2B; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG RESPONSE; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; REVIEW; STOMACH CANCER;

EID: 67949102115     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.18     Document Type: Review

References (34)

1. Ward S, Copier J, Dalgleish A: Technical challenges facing therapeutic cancer vaccines. Curr. Opin. Drug Discov. Devel. 11, 168-177 (2008).
2. Cipriani B, Fridman A, Bendtsen C et al.: Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum. Gene Ther. 19, 670-680 (2008).
3. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al.: Immunologic and clinical outcomes of a randomized Phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin. Cancer Res. 13, 6386-6395 (2007).
4. Hamid O, Solomon JC, Scotland R et al.: Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin. Cancer Res. 13, 215-222 (2007).
5. De Vries IJ, Bernsen MR, Lesterhuis WJ et al.: Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J. Clin. Oncol. 23, 5779-5787 (2005).
6. Lesterhuis WJ, de Vries IJ, Schuurhuis DH et al.: Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann. Oncol. 17, 974-980 (2006).
7. Akiyama Y, Tanosaki R, Inoue N et al.: Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J. Transl. Med. 3, 4 (2005).
8. Lesimple T, Neidhard EM, Vignard V et al.: Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin. Cancer Res. 12, 7380-7388 (2006).
9. Escobar A, Lopez M, Serrano A et al.: Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin. Exp. Immunol. 142, 555-568 (2005).
10. Lopez MN, Pereda C, Segal G et al.: Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells. J. Clin. Oncol. (2009).
11. + T cells in patients with melanoma. J. Immunol. 175, 6169-6176 (2005).
12. Nistico P, Capone I, Palermo B et al.: Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int. J. Cancer 124, 130-139 (2009).
13. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC: Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol. Immunother. 55, 1294-1298 (2006).
14. Yanagimoto H, Mine T, Yamamoto K et al.: Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci. 98, 605-611 (2007).
15. Toubaji A, Achtar M, Provenzano M et al.: Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol. Immunother. 57, 1413-1420 (2008).
16. Alexander J, Sidney J, Southwood S et al.: Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1, 751-761 (1994).
17. Barve M, Bender J, Senzer N et al.: Induction of immune responses and clinical efficacy in a Phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J. Clin. Oncol. 26, 4418-4425 (2008).
18. Bolonaki I, Kotsakis A, Papadimitraki E et al.: Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J. Clin. Oncol. 25, 2727-2734 (2007).
19. Domchek SM, Recio A, Mick R et al.: Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res. 67, 10546-10555 (2007).
20. Tsuruma T, Iwayama Y, Ohmura T et al.: Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in Phase I clinical study for patients with advanced or recurrent breast cancer. J. Transl. Med. 6, 24 (2008).
21. Chianese-Bullock KA, Irvin WP Jr, Petroni GR et al.: A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J. Immunother. 31, 420-430 (2008).
22. Mine T, Sato Y, Noguchi M et al.: Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin. Cancer Res. 10, 929-937 (2004).
23. Yajima N, Yamanaka R, Mine T et al.: Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res. 11, 5900-5911 (2005).
24. Sjoblom T, Jones S, Wood LD et al.: The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
25. Urba WJ, Nemunaitis J, Marshall F et al.: Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J. Urol. 180, 2011-2017; discussion 2017-2018 (2008).
26. Hodi FS, Butler M, Oble DA et al.: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA 105, 3005-3010 (2008).
27. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008).
28. Ilkovitch D, Lopez DM: Immune modulation by melanoma-derived factors. Exp. Dermatol. 17, 977-985 (2008).
29. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G: The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest. 118, 1991-2001 (2008).
30. + T lymphocytes by structural and functional assays. Cancer Immunol. Immunother. 57, 289-302 (2008).
31. Butterfield LH, Disis ML, Fox BA et al.: A systematic approach to biomarker discovery; preamble to 'the iSBTc-FDA taskforce on immunotherapy biomarkers'. J. Transl. Med. 6, 81 (2008).
32. Gnjatic S, Altorki NK, Tang DN et al.: NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin. Cancer Res. 15, 2130-2139 (2009).
33. Filipazzi P, Valenti R, Huber V et al.: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25, 2546-2553 (2007).
34. Selvan SR, Dillman RO, Fowler AW, Carbonell DJ, Ravindranath MH: Monitoring response to treatment in melanoma patients: potential of a serum glycomic marker. Int. J. Cancer 122, 1374-1383 (2008).